Drug intelligence / Profile preview

[18F]fluorbetaox

Development stage: Unknown
Lead developer: Avid Radiopharmaceuticals
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[18F]fluorbetaox is a radiopharmaceutical diagnostic agent used in Positron Emission Tomography (PET) imaging. It contains the radionuclide fluorine-18, which has a half-life of 110 minutes, making it suitable for PET imaging procedures. The tracer appears to be metabolized in the liver followed by gallbladder accumulation and hepatobiliary clearance. It was developed as an alternative to [11C]Palmitate for measuring fatty acid metabolism, particularly in cardiac applications.

Other names: [18F]-FluorBetaOxFBO

Targets

Amyloid-beta aggregate (N-terminal epitope)

Beyond the preview

Go deeper on [18F]fluorbetaox.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]fluorbetaox.

Explore the full profile